Serum Klotho and FGF23 Levels in Patients with Schizophrenia.
Aslı Kazğan KılıçaslanSevler YıldızBurcu Sırlıer EmirFaruk KılıçMurad AtmacaPublished in: Psychiatry and clinical psychopharmacology (2022)
Our study is the first to show significantly higher combined serum levels of fibroblast growth factor 23 and Klotho in patients with schizophrenia. The Klotho/fibroblast growth factor 23 pathway may play a role in the pathogenesis of schizophrenia. The involvement of Klotho and fibroblast growth factor 23 in inflammatory processes has the potential to provide alternative approaches to elucidate the etiopathogenesis and treatment of schizophrenia.